KONEXElectrical Equipment447690

Aiobio

₩2,010▼ 2.66%2026-10-02 close

Market Cap

₩5.6B

Turnover

₩50,691

Volume

25 shares

Shares out.

2.8M

PER

—

PBR

—

EPS

—

Dividend Yield

—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-10-02 close

Report overview

Revenue Growing, Losses Deepening

AIOBIO has secured growth catalysts in national health insurance reimbursement and a China exclusive distribution contract, but widening R&D and overseas sales expenditures are deepening losses, making the timeline to profitability the central question.

1
The QLF technology's inclusion in national health insurance reimbursement (June 2021) has established an institutional incentive for domestic dental clinics to adopt the diagnostic device
2
In early 2026, AIOBIO signed a 3-year exclusive supply contract with a Shanghai-based medical device distributor for a minimum of USD 3 million (~KRW 4.3 billion), with the QBLISS platform bundled alongside hardware
3
2024 standalone revenues grew 36.1% YoY, but operating losses widened 26.6% and net losses 32.4%, driven by overseas network build-out costs, U.S. marketing spend, and increased R&D expenditure
4
LINKDENS SaaS software analyzes and shares fluorescence imaging data via AI, providing a recurring subscription revenue stream that is structurally linked to hardware device adoption
5
As a KONEX-listed company with daily trading turnover of approximately KRW 1.8 million, liquidity is extremely limited, and ongoing monitoring of financing capacity is warranted given the company's early-stage commercial profile

Business structure

AIOBIO, founded in 2011 (originally as All-In-One Bio, rebranded in 2017), has developed and commercialized oral disease diagnostic and management solutions based on its proprietary Bio-Fluorescence Imaging System (BIS) technology.

The business model is structured around four pillars: (1) Qray-series diagnostic devices (hardware), (2) LINKDENS oral health management software (SaaS), (3) QBLISS integrated patient management platform, and (4) oral care consumables.

In the hardware segment, the Qray series—including Qraycam Pro, Qscan Plus, and Qray M—uses visible blue light to visualize dental biofilm, caries, plaque, and cracks as fluorescence images; the underlying QLF technology passed Korea's new medical technology evaluation in 2018 and serves as the primary competitive differentiator.

LINKDENS is a SaaS platform that shares real-time fluorescence imaging data within dental clinics and interprets oral status via an AI-based Multi Chromatic Analysis engine, generating recurring subscription revenue tied to installed hardware.

QBLISS is a full-cycle patient management solution covering diagnosis, patient education, motivation, management, and re-evaluation—and emerged as the central export item under the 2026 China exclusive distribution agreement.

Competitively, domestic dental imaging peers such as Vatech (Vatech/제노레이) and MicroNX operate primarily in the X-ray digital imaging space, while AIOBIO occupies a largely proprietary niche in bio-fluorescence diagnostic devices.

The company co-conducts national R&D projects with government agencies and clinical studies with university hospitals, advancing smart probe, 3D imaging, and deep learning algorithm development, with medium-term aspirations toward a Clinical Decision Support System (CDSS).

Recent trends

Per DART filings aggregated by FnGuide, 2024 standalone revenues grew 36.1% year-on-year, confirming a clear top-line growth trajectory.

The primary drivers cited include strengthened domestic sales network development and sales promotion activities, alongside the cumulative effect of expanding dental clinic adoption following the QLF-based caries examination's national health insurance reimbursement in June 2021.

However, operating losses widened 26.6% and net losses increased 32.4% over the same period, perpetuating a structure in which revenue growth has not yet translated into improved profitability.

The company's own disclosures attribute this to overseas sales network build-out costs, U.S. advertising expenditure, and increased R&D spending operating in combination.

Based on reported 2022 revenues of approximately KRW 1.1–1.2 billion, AIOBIO remains a micro-scale enterprise; even sustaining a 36% growth rate, total revenues are likely to remain in the low-to-mid single-digit billions of won.

In 2023, the company secured an investment at a reported valuation of KRW 34.1 billion from a strategic investor, approximately five times its then-KONEX market capitalization, indicating a material valuation gap.

As of June 7, 2026, shares traded at KRW 2,280 (down 0.87%), with daily turnover of approximately KRW 1.8 million, reflecting severely constrained liquidity.

The China exclusive supply contract announced in early 2026 provides a positive near-term catalyst, but revenue recognition will depend on actual shipment schedules and achievement of minimum purchase commitments.

Outlook

The medium-term growth trajectory will be determined by three axes: raising domestic health insurance-backed device penetration in dental clinics, successfully establishing the QBLISS platform in the Chinese market, and expanding the LINKDENS SaaS subscriber base.

The China exclusive contract stipulates minimum purchase targets of $600K in Year 1, $900K in Year 2, and $1.5M in Year 3, with a phased rollout anchored in Heilongjiang province; contract fulfillment thus becomes a primary variable in 2026–2028 earnings visibility.

Domestically, discussions around broadening dental insurance coverage and revisions to health management guidelines could open incremental business opportunities.

However, achieving profitability requires revenues to cross a threshold at which fixed costs are adequately covered, and given the current investment posture, a sustained period before breakeven appears likely.

Progress on the Clinical Decision Support System (CDSS) and the outcome of additional national R&D grant applications from the Ministry of Health and Welfare will be additional medium-term variables affecting both technological positioning and financial runway.

A potential transfer listing from KONEX to KOSDAQ, if qualification criteria are met, could serve as an important catalyst for liquidity improvement and broader market recognition.

Bull factors

National Health Insurance Reimbursement as Adoption Engine

The June 2021 national health insurance reimbursement provides a structural incentive for dental clinics to adopt QLF diagnostic devices, as practices can now recover associated costs through insurance billing.

With tens of thousands of dental clinics operating domestically, the gradual expansion of adopting institutions post-reimbursement is already visible in the 36.1% revenue growth reported for 2024.

As the dental care paradigm continues shifting toward early diagnosis and preventive care, demand for QLF-based examinations is structurally positioned to grow. Any further expansion of dental insurance coverage in Korea would add incremental addressable market for new service categories.

China Exclusive Contract: Validating a Platform Export Model

The exclusive nationwide China supply agreement signed in early 2026 sets minimum purchase commitments of USD 3 million over three years (~KRW 4.3 billion), and critically, it bundles hardware with the QBLISS patient management platform rather than selling devices alone.

China's large dental hospital market is actively transitioning toward digital workflows and preventive care management, making AIOBIO's solution set a strong strategic fit.

The company is building initial clinical and academic credibility in Heilongjiang, Shanghai, and Weihai, with year-over-year revenue contributions expected to scale as the contract is executed.

A successful platform-led market entry in China would serve as a key reference for subsequent expansion into other international markets.

LINKDENS SaaS: The Foundation of Recurring Revenue

LINKDENS is a SaaS model capable of generating subscription revenue independent of hardware sales, serving as a data-sharing and management platform connecting dental clinics and patients via fluorescence imaging.

Its AI-based Multi Chromatic Analysis feature delivers clinical decision support value beyond simple imaging, and the subscriber base expansion structurally improves revenue stability.

LINKDENS-series software is explicitly included in the China exclusive export contract, opening the possibility of concurrent domestic and international SaaS revenue growth.

As accumulated data volumes grow over time, AI model improvement and ancillary service development should support rising average revenue per subscriber.

Bear factors

Loss Expansion Outpacing Revenue Growth

The simultaneous 36.1% revenue growth and widening of operating losses by 26.6% and net losses by 32.4% in 2024 signals that cost leverage has yet to materialize. Overseas network build-out, U.S. marketing spend, and R&D expenditure are increasing in tandem, causing the cost structure to outpace revenue growth.

Given that total revenues remain in the low single-digit billions of won, substantial additional growth is still required to cover fixed costs. If the current investment pace continues, the need for external financing before breakeven is achieved remains a material consideration.

Extremely Low Liquidity and Small-Cap Risk

With daily trading turnover of approximately KRW 1.8 million as of June 7, 2026, institutional access is virtually impossible, and the stock is vulnerable to large price swings from even modest single transactions.

The KONEX market imposes fewer disclosure obligations and attracts limited analyst coverage relative to KOSPI/KOSDAQ, restricting investor access to information. The absence of meaningful liquidity improvement since the 2022 KONEX listing represents a persistent structural barrier to valuation re-rating.

Without a catalyst such as a transfer listing to KOSDAQ, the scope for broader market attention remains structurally constrained.

Uncertainty in International Market Execution

Actual revenue contribution from the China exclusive contract will vary significantly based on whether minimum purchase targets are met, and the Chinese medical device market presents substantial regulatory and distribution management complexity.

While U.S. advertising expenditure is being incurred, no publicly verified commercial results have emerged, leaving investment efficiency unclear. At this early stage with limited overseas operations and local networks, the risk of execution falling behind business plan targets is material.

For a resource-constrained micro-cap competing against larger global players driving dental digitalization, the path to establishing overseas market presence may prove protracted.

Risk factors

Policy & Reimbursement Risk

National health insurance reimbursement rates are subject to adjustment based on policy changes, and a tightening healthcare cost control environment cannot rule out the possibility of downward rate revisions for QLF examinations.

The ongoing tensions surrounding Korea's medical school enrollment expansion could temporarily dampen dental clinic investment sentiment for new devices. Should national health insurance coverage be extended to competing diagnostic modalities, the relative competitive advantage of QLF technology could diminish.

Government policy supporting expanded preventive dental care is broadly positive, but uncertainty around the speed and schedule of implementation remains a variable to monitor.

Financial & Liquidity Risk

With operating and net losses continuing to widen, the rate of cash burn and the level of available cash are the most critical indicators of medium-term financial stability; detailed current cash position and debt structure require direct review of DART original filings.

Should external financing become necessary, the low liquidity of the KONEX market and micro-cap profile suggest the company would likely rely on convertible bonds (CB) or third-party placement capital increases, which carry material dilution risk for existing shareholders.

The substantial gap between the investment-round valuation (~KRW 34.1 billion in 2023) and the KONEX market capitalization introduces uncertainty around future financing terms.

Market & Competitive Risk

Large global dental device manufacturers are increasingly launching integrated AI and digital solutions, potentially eroding the technological edge of specialized micro-cap players like AIOBIO. In China, rapidly growing local dental digital equipment manufacturers could intensify price competition.

There is also a key-person concentration risk typical of small companies—any departure of core technical personnel could impair the company's ability to sustain QLF-based product competitiveness.

Additionally, the learning curve and conservative adoption tendencies of dental clinic operators toward new diagnostic modalities could delay domestic penetration rate improvement.

Overall view

AIOBIO holds genuine technological and business model differentiation through its QLF technology's national health insurance reimbursement status, LINKDENS SaaS, and the QBLISS platform; the 36.1% revenue growth in 2024 demonstrates a gradual materialization of domestic commercial traction.

The China exclusive supply contract signed in early 2026 represents a meaningful near-term catalyst for accelerating top-line growth.

However, the persistent widening of operating and net losses despite revenue expansion remains the central challenge, and the lack of near-term profitability visibility is the primary source of uncertainty at this stage.

The structural liquidity constraints of the KONEX market and the micro-cap profile create significant practical barriers to investment access.

Execution of the China contract and the growth trajectory of LINKDENS subscriber institutions over the next 6–12 months are the two most important indicators to monitor; confirmed improvement in both metrics would provide grounds for a more constructive assessment.

This report is prepared for informational purposes only and does not constitute investment advice; investors are strongly encouraged to review original DART disclosures and the company's annual report in full before making any investment decision.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 9 more articles and sources

Report written 2026-06-08 · Data as of 2026-06-05

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.